Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest

Main Article Content

Kristian Reich
Eric L Simpson
Richard Langley
Richard B Warren
Antonio Costanzo
Hidehisa Saeki
Peter Almgren
Le Gjerum
Anna Carlsson
Melinda Gooderham
Andreas Pinter
Marjolein de Bruin-Weller
Andrew Blauvelt

Keywords

tralokinumab, safety, atopic dermatitis, eczema, adverse events

References

1. Nutten S. Ann Nutr Metab. 2015;66(Suppl 1):8-16

2. Weidinger S, Novak N. Lancet. 2016;387:1109-22

3. Popovic B, et al. J Mol Biol. 2017;429:208-19

4. Wollenberg A, et al. Br J Dermatol. 2021;184(3):437-449

5. Silverberg JI, et al. Br J Dermatol. 2021;184(3):450-463

6. Blauvelt A, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02345-3.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>